Quantcast

Latest Lucentis Stories

2008-06-26 09:03:12

WALTHAM, Mass., June 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Genentech/Novartis's Lucentis will become the Decision Resources' proprietary clinical gold standard by 2011 because of its ability to generate higher total sales in the United States and Europe due to its higher price. Although ophthalmologists perceive Lucentis as offering comparable efficacy to the current clinical...

2006-08-29 08:24:22

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...

2006-08-29 05:04:54

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...

2006-06-30 19:20:42

By Lisa Richwine WASHINGTON (Reuters) - A Genentech Inc. drug that reversed vision loss in some patients won U.S. approval on Friday for treating the leading cause of blindness in the elderly. Injected into the eye monthly, the drug Lucentis maintained vision in 95 percent of patients with the wet form of age-related macular degeneration (AMD) who were treated for 12 months. Eyesight improved in one-third of patients, the Food and Drug Administration said. "The 95 percent retention...

2005-07-18 11:59:19

NEW YORK (Reuters) - Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections. The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal. Genentech has said that U.S....


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.